Related references
Note: Only part of the references are listed.Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19
Ziad Bakouny et al.
JAMA ONCOLOGY (2023)
Association of active immunotherapy with outcomes in cancer patients with COVID-19: a systematic review and meta-analysis
Chang Cao et al.
AGING-US (2022)
A prospective study of 12-week respiratory outcomes in COVID-19-related hospitalisations
Aditi S. Shah et al.
THORAX (2021)
At the Crossroads: COVID-19 and Immune-Checkpoint Blockade for Cancer
Marina Chiara Garassino et al.
CANCER IMMUNOLOGY RESEARCH (2021)
The effect of anticancer treatment on cancer patients with COVID-19: A systematic review and meta-analysis
Hanqing Liu et al.
CANCER MEDICINE (2021)
Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition
Aljosja Rogiers et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
COVID and Lung Cancer
Luana Calabro et al.
CURRENT ONCOLOGY REPORTS (2021)
Perspectives on COVID-19 and cancer immunotherapy: a review series
Jason D. Goldman et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Severity of COVID-19 in patients with lung cancer: evidence and challenges
Antonio Passaro et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium
P. Grivas et al.
ANNALS OF ONCOLOGY (2021)
Smoking is associated with worse outcomes of COVID-19 particularly among younger adults: a systematic review and meta-analysis
Roengrudee Patanavanich et al.
BMC PUBLIC HEALTH (2021)
Nanoparticle-Based Therapies for Turning Cold Tumors Hot: How to Treat an Immunosuppressive Tumor Microenvironment
Giulio Giustarini et al.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY (2021)
Immune checkpoint inhibitors in lymphoma: challenges and opportunities
Haris Hatic et al.
ANNALS OF TRANSLATIONAL MEDICINE (2021)
Turning cold tumors into hot tumors by improving T-cell infiltration
Yuan-Tong Liu et al.
THERANOSTICS (2021)
Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC
Makoto Nishio et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Primary and acquired resistance mechanisms to immune checkpoint inhibition in Hodgkin lymphoma
Johanna Veldman et al.
CANCER TREATMENT REVIEWS (2020)
An interactive web-based dashboard to track COVID-19 in real time
Ensheng Dong et al.
LANCET INFECTIOUS DISEASES (2020)
Covid-19-Navigating the Uncharted
Anthony S. Fauci et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
A systematic review: Role of systemic therapy on treatment and prevention of brain metastasis in renal cell carcinoma
Emre Yekeduz et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2020)
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
Nicole M. Kuderer et al.
LANCET (2020)
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
Fei Zhou et al.
LANCET (2020)
Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study
Jianbo Tian et al.
LANCET ONCOLOGY (2020)
Frequently asked questions regarding SARS-CoV-2 in cancer patients-recommendations for clinicians caring for patients with malignant diseases
Marie Von Lilienfeld-Toal et al.
LEUKEMIA (2020)
Challenges in lung cancer therapy during the COVID-19 pandemic
Luana Calabro et al.
LANCET RESPIRATORY MEDICINE (2020)
Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review
Keisuke Onoi et al.
JOURNAL OF CLINICAL MEDICINE (2020)
COVID-19 pneumonia and immune-related pneumonitis: critical issues on differential diagnosis, potential interactions, and management
Marco Russano et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2020)
Immune-Checkpoint Blockade Therapy in Lymphoma
Ayumi Kuzume et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease An International Multicenter Study
Thomas M. Drake et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2020)
Cancer, COVID-19, and Antiviral Immunity: The CAPTURE Study
Lewis Au et al.
CELL (2020)
COVID-19 pneumonia: CD8+ T and NK cells are decreased in number but compensatory increased in cytotoxic potential
Yujie Jiang et al.
CLINICAL IMMUNOLOGY (2020)
A brief-review of the risk factors for covid-19 severity
J. E. Rod et al.
REVISTA DE SAUDE PUBLICA (2020)
Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC)-novel approaches and future outlook
Lena Horvath et al.
MOLECULAR CANCER (2020)
The impact of the COVID-19 pandemic on lung cancer patients
Zhou Sha et al.
ANNALS OF PALLIATIVE MEDICINE (2020)
Turning Cold into Hot: Firing up the Tumor Microenvironment
Qianqian Duan et al.
TRENDS IN CANCER (2020)
Mortality Rate and Predictors of Mortality in Hospitalized COVID-19 Patients with Diabetes
Dilaram Acharya et al.
HEALTHCARE (2020)
COVID-19 in cancer patients: risk, clinical features, and management
Cuiwei Liu et al.
CANCER BIOLOGY & MEDICINE (2020)
Impact of COVID -19 in cancer patients on severity of disease and fatal outcomes: A systematic review and meta-analysis
Abhijeet Ashok Salunke et al.
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS (2020)
Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial
Yi-Long Wu et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
Martin Reck et al.
LANCET RESPIRATORY MEDICINE (2019)
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Tony S. K. Mok et al.
LANCET (2019)
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
Howard West et al.
LANCET ONCOLOGY (2019)
The emerging treatment landscape of targeted therapy in non-small-cell lung cancer
Min Yuan et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Host Immune Response to Influenza A Virus Infection
Xiaoyong Chen et al.
FRONTIERS IN IMMUNOLOGY (2018)
Immune Evasion in Pancreatic Cancer: From Mechanisms to Therapy
Neus Martinez-Bosch et al.
CANCERS (2018)
Pembrolizumab plus Chemotherapy in Lung Cancer
Manuel D. Gil-Sierra et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors
Saman Maleki Vareki
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Update on immune checkpoint inhibitors in gynecological cancers
Valerie Heong et al.
JOURNAL OF GYNECOLOGIC ONCOLOGY (2017)
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Lesley Seymour et al.
LANCET ONCOLOGY (2017)
Immune checkpoint blockade in lymphoid malignancies
Gita Thanarajasingam et al.
FEBS JOURNAL (2016)
Immune checkpoint inhibition in lymphoid disease
Toby A. Eyre et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Immune infiltration and prostate cancer
Amy Strasner et al.
FRONTIERS IN ONCOLOGY (2015)
Randomized Phase III Trial of Single-Agent Pemetrexed Versus Carboplatin and Pemetrexed in Patients With Advanced Non-Small-Cell Lung Cancer and Eastern Cooperative Oncology Group Performance Status of 2
Mauro Zukin et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Share Paper
